Related references
Note: Only part of the references are listed.Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): An international systematic review and meta-analysis
Leila T. Tchelebi et al.
CANCER (2020)
A prospective observational study of the clinical and pathological impact of stereotactic body radiotherapy (SBRT) as a neoadjuvant strategy of chemoradiation in pancreatic cancer
X. Chen-Zhao et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2020)
Stereotactic body radiotherapy vs conventionally fractionated chemoradiation in locally advanced pancreatic cancer: A multicenter case-control study (PAULA-1)
Alessandra Arcelli et al.
CANCER MEDICINE (2020)
Dose Escalation in Stereotactic Body Radiation Therapy for Pancreatic Cancer A Meta-Analysis
Nicholas G. Zaorsky et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2019)
Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer A Phase 2 Clinical Trial
Janet E. Murphy et al.
JAMA ONCOLOGY (2019)
Stereotactic body radiation therapy for locally advanced pancreatic cancer
Jinhong Jung et al.
PLOS ONE (2019)
Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen
Lauren Henke et al.
RADIOTHERAPY AND ONCOLOGY (2018)
Dosimetric analysis of stereotactic rotational versus static intensity-modulated radiation therapy for pancreatic cancer
I. Cho et al.
CANCER RADIOTHERAPIE (2018)
Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Cancer: A Systematic Review and Pooled Analysis of 19 Trials
Fausto Petrelli et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer
Joseph J. Park et al.
ACTA ONCOLOGICA (2017)
Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review
Susanna W. L. de Geus et al.
CANCER (2017)
Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation
Jim Zhong et al.
CANCER (2017)
Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer
Tetsuhito Muranaka et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2017)
Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas
Matthew H. G. Katz et al.
BMC CANCER (2017)
Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer
Stacey M. Stein et al.
BRITISH JOURNAL OF CANCER (2016)
Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation
Sunil Krishnan et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2016)
A Phase 1 Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer After Modified FOLFIRINOX (NCT01446458)
Walid L. Shaib et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2016)
Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib The LAP07 Randomized Clinical Trial
Pascal Hammel et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
Mustafa Suker et al.
LANCET ONCOLOGY (2016)
Comparing outcomes of stereotactic body radiotherapy with intensity-modulated radiotherapy for patients with locally advanced unresectable pancreatic cancer
Jang-Chun Lin et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2015)
Phase 2 Multi-institutional Trial Evaluating Gemcitabine and Stereotactic Body Radiotherapy for Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma
Joseph M. Herman et al.
CANCER (2015)
Single-versus Multifraction Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma: Outcomes and Toxicity
Erqi L. Pollom et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety
Marie K. Gurka et al.
RADIATION ONCOLOGY (2013)
Stereotactic Body Radiation Therapy for Nonresectable Tumors of the Pancreas
Kush Goyal et al.
JOURNAL OF SURGICAL RESEARCH (2012)
INDUCTION GEMCITABINE AND STEREOTACTIC BODY RADIOTHERAPY FOR LOCALLY ADVANCED NONMETASTATIC PANCREAS CANCER
Anand Mahadevan et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
SINGLE-FRACTION STEREOTACTIC BODY RADIATION THERAPY AND SEQUENTIAL GEMCITABINE FOR THE TREATMENT OF LOCALLY ADVANCED PANCREATIC CANCER
Devin Schellenberg et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial
Patrick J. Loehrer et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Pancreatic Cancer
Manuel Hidalgo
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment
Youjin Lee et al.
BLOOD (2009)
Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer.: Definitive results of the 2000-01 FFCD/SFRO study
B. Chauffert et al.
ANNALS OF ONCOLOGY (2008)
Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer
Devin Schellenberg et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2008)
Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer
AC Koong et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2005)
Tumor response to radiotherapy regulated by endothelial cell apoptosis
M Garcia-Barros et al.
SCIENCE (2003)
Share Paper
